Karny Jacoby, MD
Urology · Mountlake Terrace, WANPI 1841274412
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Medtronic at 51.2% of the total. Among urology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $55.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Coloplast$1K
- Boston Scientific$1K
- Axonics, Inc.$1K
- Procept Biorobotics Corporation$812
- Sumitomo Pharma America, Inc.$312
- plus $2K from 21 others
Across 33 payments — averaging $3286.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$104K
- Ipsen Innovation$2K
- Urovant Sciences Inc$2K
What the payments were for
- Travel & lodging$5,65640%
- Food & beverage$8,20759%
- Education$1391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 118 | $7,163 |
| Coloplast | 24 | $1,455 |
| Boston Scientific | 14 | $1,355 |
| Axonics, Inc. | 14 | $1,305 |
| Procept Biorobotics Corporation | 6 | $812 |
| Sumitomo Pharma America, Inc. | 12 | $312 |
| Laborie Medical Technologies Corp. | 3 | $204 |
| Astellas Pharma US Inc | 7 | $162 |
| Bayer | 2 | $132 |
| Caldera Medical, Inc | 3 | $124 |
| AbbVie | 3 | $119 |
| Therapeuticsmd, Inc. | 8 | $115 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $105 |
| 180 Medical, Inc. | 4 | $101 |
| Urovant Sciences Inc | 7 | $93 |
| Antares Pharma, Inc. | 6 | $91 |
| Mayne Pharma Commercial LLC | 7 | $63 |
| Convatec Inc. | 2 | $48 |
| Johnson & Johnson | 1 | $41 |
| AMAG Pharmaceuticals, Inc. | 2 | $31 |
| Ambu Inc. | 1 | $29 |
| Pfizer | 2 | $27 |
| KARL Storz Endoscopy-america | 1 | $27 |
| Calyxo, Inc. | 1 | $25 |
| Astellas Pharma Global Development | 1 | $23 |
| Myriad Genetic Laboratories, Inc. | 1 | $19 |
| Teleflex LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$3,958
- SOLYX$1,061
- Axonics r-SNM System$1,003
- Bulkamid$838
- AquaBeam Robotic System$705
- ALTIS$625
- TITAN$226
How this compares
$14,002 in reported general payments places this provider in the 90th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 115 | $103,079 |
| Estradiol | 269 | $38,251 |
| MyrbetriqMirabegron | 29 | $20,304 |
| Methenamine Hippurate | 93 | $8,891 |
| Potassium Citrate ErPotassium Citrate | 16 | $2,612 |
| YuvafemEstradiol | 11 | $1,447 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $275 |
| Tamsulosin Hcl | 17 | $235 |
| Finasteride | 34 | $209 |
| Cephalexin | 27 | $178 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $142 |
| Ciprofloxacin Hcl | 28 | $67 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $41 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $312 | $103,079115 claims |
| Astellas Pharma US IncMyrbetriq | $162 | $20,30429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 274 urology providers in Washington.
Other urology in Mountlake Terrace
- James PorterSeattle$471K
- Marah HehemannSeattle$213K
- Raymond LanceSpokane$211K
- Thomas WalshSeattle$186K
- Alvaro LucioniSeattle$148K
- Una LeeSeattle$116K
- George SchadeSeattle$78K
- Kevin OstrowskiKirkland$64K
- Marco SalazarEdmonds$58K
- Anthony BuiVancouver$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.